Baillie Gifford & Co’s AstraZeneca AZN Stock Holding History

Baillie Gifford & Co’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-228	Closed	-$31.7K	–	309
2023 Q1	$31.7K	Buy	228 +28	+14%	+$3.77K	﹤0.01%	309
2022 Q4	$27.1K	Hold	200	–	–	﹤0.01%	321
2022 Q3	$22K	Hold	200	–	–	﹤0.01%	319
2022 Q2	$26K	Hold	200	–	–	﹤0.01%	317
2022 Q1	$27K	Hold	200	–	–	﹤0.01%	327
2021 Q4	$23K	Hold	200	–	–	﹤0.01%	358
2021 Q3	$24K	Buy	+200	New	+$23.3K	﹤0.01%	342

Other funds holding AZN

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

GQG Partners Ft. Lauderdale, Florida $53.8B AUM 19.23% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Baillie Gifford & Co's AZN Position: Q2 2023 in Review

Baillie Gifford & Co sold out of AstraZeneca (AZN) in Q2 2023, closing a stake of 228 shares — an estimated $31.7K sold.

Baillie Gifford & Co first reported a position in AZN in Q3 2021 and held it in 7 quarters. The position peaked at $31.7K in Q1 2023. 1,090 funds tracked by Wall St. Rank hold AZN as of Q2 2023.

Baillie Gifford & Co reported no remaining AstraZeneca position as of Q2 2023 after selling out during the quarter.
Baillie Gifford & Co sold 228 AstraZeneca shares in Q2 2023, an estimated $31.7K.
Baillie Gifford & Co first reported a position in AstraZeneca in Q3 2021 and held it in 7 quarters.
Baillie Gifford & Co's AstraZeneca position peaked at $31.7K in Q1 2023.
1,090 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2023.

Based on Baillie Gifford & Co's 13F filing for Q2 2023, filed 28 Jul 2023.